Article

1 Iconography
1 Complement
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    7 1 0 0


Joint Bone Spine
Volume 85, n° 6
pages 747-753 (décembre 2018)
Doi : 10.1016/j.jbspin.2018.01.008
accepted : 11 January 2018
Original Articles

Gout drugs use and risk of cancer: A case-control study
 

Hsuan-Chia Yang a, b, Phung Anh Alex Nguyen b, c, Mohaimenul Islam b, d, Chih-Wei Huang e, Tahmina Nasrin Poly b, d, Usman Iqbal b, f, 1, Yu-Chuan Jack Li a, b, g, , 1
a College of Medicine Science and Technology, Taipei Medical University, 110 Taipei, Taiwan 
b International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan 
c Department of Population and Quantitative Health Sciences, Case Western Reserve University, United States 
d Graduate Institute of Biomedical Informatics, Taipei Medical University, 110 Taipei, Taiwan 
e Joint Commission of Taiwan, 110 New Taipei City, Taiwan 
f Master's Program in Global Health and Development Department, College of Public Health, Taipei Medical University, 110 Taipei, Taiwan 
g Department of Dermatology, Taipei Medical University, Wan Fang Hospital, 110 Taipei, Taiwan 

Corresponding author. Graduate Institute of Biomedical Informatics, Taipei Medical University, 250, Wu-Hsing Street, 110 Taipei, Taiwan.Graduate Institute of Biomedical Informatics, Taipei Medical University, 250, Wu-Hsing Street, 110 Taipei, Taiwan.
Highlights

Concerns have been raised regarding the risk of gout medications to cancer risk.
Having lack of epidemiological evidence, this study shows the association between gout drugs and risk of cancer.
Gout drugs are significantly increased risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.

The full text of this article is available in PDF format.
Abstract
Objective

Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.

Methods

We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.

Results

We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13).

Conclusion

In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.

The full text of this article is available in PDF format.

Keywords : Gout drugs, Breast cancer, Cervical cancer, Allopurinol, Pharmacoepidemiology etc.


1  Equal contribution corresponding author.


© 2018  Société française de rhumatologie@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline